ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์ด๋ž€?

ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๊ฑฐ๋‚˜ ์„ญ์ทจํ•˜๊ฑฐ๋‚˜ ์ฃผ์ž…ํ•˜๋Š” ํ˜•ํƒœ์˜ ํ—ฌ์Šค์ผ€์–ด ์ œํ’ˆ์— ์‚ฌ์šฉ๋˜๋Š” ์„ฑ๋ถ„์ž…๋‹ˆ๋‹ค. ์‹ ์ฒด ๊ตฌ์กฐ๋ฅผ ๊ตฌ์„ฑํ•˜๋Š” ์„ฑ๋ถ„์œผ๋กœ ์ „์‹ ์—์„œ ์ƒ์„ฑ๋˜๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ D-๊ธ€๋ฃจ์ฟ ๋ก ์‚ฐ(D-glucuronic acid)๊ณผ N-์•„์„ธํ‹ธ-D-๊ธ€๋ฃจ์ฝ”์‚ฌ๋ฏผ(N-acetyl-D-glucosamine)์ด๋ผ๋Š” ๋‹น ๋ถ„์ž๊ฐ€ ๊ต๋Œ€๋กœ ์—ฐ๊ฒฐ๋˜์–ด ๊ธด ์‚ฌ์Šฌ์„ ์ด๋ฃฌ ๊ตฌ์กฐ๋กœ ์ด๋ฃจ์–ด์ ธ ์žˆ์Šต๋‹ˆ๋‹ค. ๋˜ํ•œ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ์ˆ˜๋ถ„์„ ํ’๋ถ€ํ•˜๊ฒŒ ๋ณด์œ ํ•˜์—ฌ ํ”ผ๋ถ€ ๋ฐ ๊ด€์ ˆ ์กฐ์ง์— ์ˆ˜๋ถ„์„ ๊ณต๊ธ‰ํ•˜๊ณ  ์œคํ™œ ์ž‘์šฉ์„ ํ•ฉ๋‹ˆ๋‹ค.

์Šคํ‚จ์ผ€์–ด ์ œํ’ˆ์— ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์ด ์‚ฌ์šฉ๋˜๋Š” ์ด์œ 

์ฒด๋‚ด ๊ฒฐํ•ฉ์กฐ์ง์—์„œ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์˜ ์ƒ์„ฑ๊ณผ ๋ถ„ํ•ด๋Š” ๋น ๋ฅธ ์†๋„๋กœ ์ด๋ฃจ์–ด์ง‘๋‹ˆ๋‹ค. ํ”ผ๋ถ€์— ๋ถ„ํฌํ•˜๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๋ณดํ†ต ํ•˜๋ฃจ๋„ ์ง€๋‚˜์ง€ ์•Š์•„ ์ƒˆ๋กœ์šด ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์œผ๋กœ ๊ต์ฒด๋ฉ๋‹ˆ๋‹ค. ์—ฐ๊ณจ์กฐ์ง์˜ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๊ธธ๋ฉด ๋ช‡ ์ฃผ ๋™์•ˆ ์œ ์ง€๋œ ํ›„ ๋ถ„ํ•ด๋˜๊ธฐ๋„ ํ•ฉ๋‹ˆ๋‹ค.

๋‚˜์ด๊ฐ€ ๋“ค์ˆ˜๋ก ํ”ผ๋ถ€๋ฅผ ๋น„๋กฏํ•˜์—ฌ ๋‹ค์–‘ํ•œ ์ฒด๋‚ด ์กฐ์ง์—์„œ ์ƒ์„ฑ๋˜๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์˜ ์–‘์€ ๊ฐ์†Œํ•ฉ๋‹ˆ๋‹ค. ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ๊ฐ์†Œ๋กœ ์ธํ•œ ์ˆ˜๋ถ„ ์†์‹ค์€ ํ”ผ๋ถ€๊ฐ€ ๋…ธํ™”ํ•˜๊ณ  ํƒ„๋ ฅ์ด ์ €ํ•˜๋˜๊ณ  ํ‡ดํ™”๊ฐ€ ์ด‰์ง„๋˜๋Š” ์ฃผ์š” ์›์ธ์ž…๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ํ”ผ๋ถ€ ์†์ƒ์€ ์žฅ๊ธฐ์ ์œผ๋กœ ์ฃผ๋ฆ„, ์น™์น™ํ•œ ํ”ผ๋ถ€ํ†ค, ํ”ผ๋ถ€ ์ฒ˜์ง์œผ๋กœ ์ด์–ด์งˆ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. 

์ด ๋•Œ๋ฌธ์— ํ”ผ๋ถ€ ๊ฑด๊ฐ•์„ ๊ฐœ์„ ํ•˜๊ณ  ๋…ธํ™”๋ฅผ ์–ต์ œํ•  ์ˆ˜ ์žˆ๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์— ๋Œ€ํ•œ ์‚ฌ๋žŒ๋“ค์˜ ๊ด€์‹ฌ์ด ๋œจ๊ฒ์Šต๋‹ˆ๋‹ค. ์—ฐ๊ตฌ์— ๋”ฐ๋ฅด๋ฉด ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๋‹ค๋ฅธ ํšจ๋Šฅ๋„ ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค.

๊ด‘๋…ธํ™”: ํ–‡๋น›์œผ๋กœ ์ธํ•œ ํ”ผ๋ถ€ ์†์ƒ

ํ–‡๋น›์€ ํ”ผ๋ถ€ ์กฐ๊ธฐ ๋…ธํ™”์˜ ์ค‘์š”ํ•œ ์›์ธ ์ค‘ ํ•˜๋‚˜๋กœ, ํ”ผ๋ถ€ ๋…ธํ™”์˜ 80%๋Š” ์ผ๊ด‘ ๋…ธ์ถœ์— ์˜ํ•œ ๊ฒƒ์œผ๋กœ ์ถ”์ •๋ฉ๋‹ˆ๋‹ค. ์—ฐ๊ตฌ์— ๋”ฐ๋ฅด๋ฉด ์ƒ์ฅ๋Š” ํ–‡๋ณ•์„ 5๋ถ„๋งŒ ์ฌ์–ด๋„ ํ”ผ๋ถ€์˜ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ˆ˜์น˜๊ฐ€ ๋ณ€ํ™”ํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ˆ˜์น˜ ๋ณ€ํ™”๋Š” ํ”ผ๋ถ€๊ฐ€ ์†์ƒ๋˜์—ˆ์Œ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ํ”ผ๋ถ€๊ฐ€ ํƒœ์–‘์— ์žฅ๊ธฐ๊ฐ„ ๋…ธ์ถœ๋˜๋ฉด ํ–‡๋ณ•์— ์†์ƒ๋œ ํ”ผ๋ถ€ ์ „๋ฐ˜์— ๊ฑธ์ณ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ˆ˜์น˜๊ฐ€ ๊ฐ์†Œํ•˜๊ณ  ํ‰ํ„ฐ ํ˜•์„ฑ๊ณผ ์œ ์‚ฌํ•œ ๊ณผ์ •์ด ์ผ์–ด๋‚ฉ๋‹ˆ๋‹ค.

๋น„ํƒ€๋ฏผD๋ฅผ ์–ป๊ธฐ ์œ„ํ•ด ์–ด๋Š ์ •๋„ ํ–‡๋ณ•์„ ์ฌ˜ ํ•„์š”๋Š” ์žˆ์Šต๋‹ˆ๋‹ค. ๊ทธ๋Ÿด ๊ฒฝ์šฐ ์–ผ๊ตด ํ”ผ๋ถ€์˜ ๊ด‘๋…ธํ™”๋ฅผ ์ตœ์†Œํ™”ํ•  ์ˆ˜ ์žˆ๋„๋ก ๋จธ๋ฆฌ๋‚˜ ๋ชฉ๋ณด๋‹ค ํŒ”๋‹ค๋ฆฌ๋ฅผ ํ–‡๋ณ•์— ๋…ธ์ถœํ•˜๋Š” ๊ฒƒ์ด ์ข‹์Šต๋‹ˆ๋‹ค. ๋ถ€์ž‘์šฉ์ด ์—†๋Š” ์ฒœ์—ฐ ์„ฑ๋ถ„์˜ ์ž์™ธ์„  ์ฐจ๋‹จ์ œ๋„ ์ผ๊ด‘ ๋…ธ์ถœ์— ์˜ํ•œ ๊ด‘๋…ธํ™”๋ฅผ ์–ต์ œํ•˜๋Š” ๋ฐ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ”ผ๋ถ€์— ์ฃผ์ž…ํ•˜๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ํ•„๋Ÿฌ

์ตœ๊ทผ ๋“ค์–ด ํ•ญ๋…ธํ™” ์น˜๋ฃŒ๊ฐ€ ์ธ๊ธฐ๋ฅผ ๋Œ๊ณ  ์žˆ๋Š” ๊ฐ€์šด๋ฐ ์ Š์–ด ๋ณด์ด๊ธฐ ์œ„ํ•ด ๋ณดํ†ก์Šค์™€ ํ•„๋Ÿฌ ์‹œ์ˆ ์„ ๋ฐ›๋Š” ์‚ฌ๋žŒ์ด ๋งŽ์Šต๋‹ˆ๋‹ค. ํ”ผ๋ถ€์— ์ฃผ์ž…ํ•˜๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ํ•„๋Ÿฌ๋Š” ํ”ผ๋ถ€๋ฅผ ํŒฝํŒฝํ•˜๊ฒŒ ํ•  ๋ชฉ์ ์œผ๋กœ ์‚ฌ์šฉ๋ฉ๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ํ•„๋Ÿฌ ์‹œ์ˆ ์€ ๋งŽ์€ ์‚ฌ๋žŒ์ด ์ด์šฉํ•˜๊ณ  ์žˆ์ง€๋งŒ ์‹ค์ œ๋กœ ํšจ๋Šฅ์ด ์žˆ๋Š”์ง€, ์–ด๋–ค ๋ถ€์ž‘์šฉ์ด ์žˆ๋Š”์ง€ ์‹ ์ค‘ํ•˜๊ฒŒ ์‚ดํŽด๋ณผ ํ•„์š”๊ฐ€ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ•„๋Ÿฌ๋Š” ์ผ๋ฐ˜์ ์œผ๋กœ ์•ˆ์ „ํ•˜์ง€๋งŒ ๊ฐ€๋” ์‹ฌ๊ฐํ•œ ๋ถ€์ž‘์šฉ์„ ์ผ์œผํ‚ฌ ์ˆ˜ ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ์Šต๋‹ˆ๋‹ค. ๋ˆˆ๋ฌผ๊ธธ ๊ธฐํ˜•์— ๋Œ€ํ•œ ์—ฐ๊ตฌ์—์„œ๋Š” ํ”ผ๋ถ€ ์ฃผ์ž…์šฉ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ๋“ฑ ์„ฑํ˜•์šฉ ํ•„๋Ÿฌ์˜ ๋ถ€์ž‘์šฉ์ด ์šฐ๋ คํ•  ๋งŒํ•œ ์ˆ˜์ค€์ธ ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ๋ˆˆ๋ฌผ๊ธธ ๊ธฐํ˜•์€ ๋ˆˆ๋ฐ‘ ์ง€๋ฐฉ ์ฃผ๋จธ๋‹ˆ๊ฐ€ ๋‘๋“œ๋Ÿฌ์ง€๋Š” ์ฆ์ƒ์ด ํŠน์ง•์ธ ์งˆํ™˜์ž…๋‹ˆ๋‹ค.

์ด ์—ฐ๊ตฌ์—์„œ ํ•„๋Ÿฌ ์‹œ์ˆ ์ž ์ค‘ ๊ฑฐ์˜ ์ ˆ๋ฐ˜์—๊ฒŒ ์ง€์—ฐ์„ฑ ๋ถ€์ข…์ด ์ƒ๊ฒผ๊ณ  4๋ช… ์ค‘ 1๋ช…์—๊ฒŒ ๋ฉ์–ด๋ฆฌ ๋˜๋Š” ๊ฒฐ์ ˆ์ด ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ๋˜ํ•œ 6๋ช… ์ค‘ 1๋ช…์€ ์ง€๋ฐฉ์ด ๋ˆˆ์— ๋Œ ์ •๋„๋กœ ํ”ผ๋ถ€์— ์ถ•์ ๋˜๋Š” ์ฆ์ƒ์ธ ํ™ฉ์ƒ‰์ข…์ด ์ƒ๊ฒผ์Šต๋‹ˆ๋‹ค. ์‹œ์ˆ  ๋ถ€์œ„์—์„œ ํ•„๋Ÿฌ๊ฐ€ ์ด๋™ํ•œ ํ˜„์ƒ์€ 13๋ช… ์ค‘ 1๋ช…์—๊ฒŒ ๋ฐœ์ƒํ–ˆ์œผ๋ฉฐ ํ”ผ๋ถ€ ๋ณ€์ƒ‰์€ 30๋ช… ๊ฐ€์šด๋ฐ 1๋ช…์—๊ฒŒ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค.

๋“œ๋ฌผ๊ธฐ๋Š” ํ•˜์ง€๋งŒ ํ•„๋Ÿฌ ์‹œ์ˆ ๋กœ ์ธํ•ด ์–ผ๊ตด๋กœ ์œ ์ž…๋˜๋Š” ํ˜ˆ๋ฅ˜๊ฐ€ ์ค„์–ด ํ•ด๋‹น ํ”ผ๋ถ€ ์กฐ์ง์ด ๊ดด์‚ฌํ•˜๋Š” ๊ฒฝ์šฐ๋„ ์žˆ์Šต๋‹ˆ๋‹ค. ์‹œ๋ ฅ ์ƒ์‹ค, ๋‡Œ๋ถ€์ข… ๊ฐ™์€ ๋ถ€์ž‘์šฉ๋„ ๋“œ๋ฌผ๊ฒŒ ๋ฐœ์ƒํ•ฉ๋‹ˆ๋‹ค. ๋‹คํ–‰ํžˆ๋„ ์ฃผ์ž…ํ˜• ํ•„๋Ÿฌ ์ด์™ธ์˜ ํ˜•ํƒœ๋กœ ์‚ฌ์šฉ๋˜๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๋ถ€์ž‘์šฉ์ด ์—†์–ด ๋ณด์ž…๋‹ˆ๋‹ค.

ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์˜ ํ™œ์šฉ ํ˜•ํƒœ

๋…ธํ™”๋ฅผ ์ง€์—ฐ์‹œํ‚ค๊ฑฐ๋‚˜ ์—ญ์ „์‹œํ‚ค๋Š” ๋ฐฉ๋ฒ•์— ๋Œ€ํ•œ ์‚ฌ๋žŒ๋“ค์˜ ๊ด€์‹ฌ์ด ๋†’์•„์ง€๋Š” ๊ฐ€์šด๋ฐ ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๋Š” ๋‹ค์–‘ํ•œ ์ œ์ œ์˜ ํšจ๊ณผ๊ฐ€ ์†์† ๋ฐํ˜€์ง€๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์ž„์ƒ์—ฐ๊ตฌ์— ๋”ฐ๋ฅด๋ฉด ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๋Š” ์Šคํ‚จ์ผ€์–ด ์ œํ’ˆ ์„ฑ๋ถ„ ์ค‘์—์„œ ๋น„ํƒ€๋ฏผA, ๋ ˆํ‹ฐ๋…ธ์ด๋“œ(Retinoid), ์•ŒํŒŒํžˆ๋“œ๋ก์‹œ์‚ฐ(Alpha-hydroxy acid)ํ•ญ์‚ฐํ™”์ œํŽฉํƒ€์ด๋“œ(Peptide), ํ•˜์ผ๋ฃจ๋ก ์‚ฐ ๋“ฑ์€ ํ”ผ๋ถ€ ๋…ธํ™” ์ฆ์ƒ์„ ์™„ํ™”ํ•˜๋Š” ๊ฒƒ์œผ๋กœ ์ž…์ฆ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.

ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๋Š” ์ œ์ œ

ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๊ฑฐ๋‚˜ ๊ฒฝ๊ตฌ๋กœ ์„ญ์ทจํ•˜๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ œ์ œ๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ํ•„๋Ÿฌ๋ณด๋‹ค ๋ถ€์ž‘์šฉ์ด ํ›จ์”ฌ ์ ์–ด ๋Œ€์ฒด๋กœ ์•ˆ์ „ํ•ฉ๋‹ˆ๋‹ค. ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๋Š” ์Šคํ‚จ์ผ€์–ด ์ œํ’ˆ์€ ํ”ผ๋ถ€ ์™ธ๊ด€์„ ๊ฐœ์„ ํ•˜๊ณ  ๋…ธํ™” ์ฆ์ƒ์„ ๊ฐ์†Œ์‹œํ‚ฌ ์ˆ˜ ์žˆ๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์„ ํ•จ์œ ํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Šต๋‹ˆ๋‹ค.

ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์˜ ์žฅ์  ์ค‘ ํ•˜๋‚˜๋Š” ์‚ฌ์šฉ์„ ์ค‘๋‹จํ•œ ํ›„์—๋„ ํšจ๊ณผ๊ฐ€ ์ง€์†๋œ๋‹ค๋Š” ์ ์ž…๋‹ˆ๋‹ค. ๋˜ํ•œ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ์„ธํฌ ์žฌ์ƒ์„ ์ด‰์ง„ํ•˜๊ณ  ์—ผ์ฆ์„ ๊ฐ์†Œ์‹œํ‚ค๋ฉฐ ์ถ”๊ฐ€์ ์ธ ๊ฒฐํ•ฉ์กฐ์ง์˜ ์ƒ์„ฑ์„ ์ฆ๊ฐ€์‹œํ‚ต๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ํšจ๋Šฅ ๋•๋ถ„์— ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ œ์ œ๋Š” ์ผ์ • ๊ธฐ๊ฐ„ ํ›„์— ์‚ฌ์šฉ์„ ์ค‘๋‹จํ•˜๋”๋ผ๋„ ์žฅ๊ธฐ์ ์œผ๋กœ ํ”ผ๋ถ€ ๊ฐœ์„ ์„ ๋„์šธ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํฅ๋ฏธ๋กญ๊ฒŒ๋„ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ํ”ผ๋ถ€ ์ƒ์ฒ˜ ๋ฐ ์†์ƒ์„ ์น˜์œ ํ•˜๋Š” ๋ฐ๋„ ๋„์›€์ด ๋˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ์ž„์ƒ์‹œํ—˜์— ๋”ฐ๋ฅด๋ฉด ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๋งŒ์„ฑ ๋‹ค๋ฆฌ ๊ถค์–‘์„ ๋น„๋กฏํ•œ ๋‹ค์–‘ํ•œ ์ƒ์ฒ˜๋ฅผ ์น˜๋ฃŒํ•˜๋Š” ๋ฐ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํ•˜์ง€ ํ˜ˆ์•ก์ˆœํ™˜ ์žฅ์• ๋กœ ์ธํ•œ ๊ถค์–‘์€ ๋งŒ์„ฑํ™”๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„ ์น˜๋ฃŒํ•˜๊ธฐ๊ฐ€ ๊นŒ๋‹ค๋กญ์Šต๋‹ˆ๋‹ค. ์—ฐ๊ตฌ์—์„œ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์ด ํ•จ์œ ๋œ ๊ฑฐ์ฆˆ ํŒจ๋“œ๋ฅผ ์‚ฌ์šฉํ•œ ๊ฒฝ์šฐ์™€ ๋งŒ์„ฑ ์ •๋งฅ ๊ถค์–‘์— ๋Œ€ํ•œ ํ‘œ์ค€ ์น˜๋ฃŒ๋ฅผ ์‹ค์‹œํ•œ ๊ฒฝ์šฐ์˜ ํšจ๊ณผ๋ฅผ ๋น„๊ตํ–ˆ์Šต๋‹ˆ๋‹ค. ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์œผ๋กœ ์น˜๋ฃŒํ•œ ํ”ผํ—˜์ž์˜ 40%๊ฐ€ ์™„์ „ํžˆ ์น˜์œ ๋œ ๋ฐ˜๋ฉด, ํ‘œ์ค€ ์น˜๋ฃŒ๋งŒ ๋ฐ›์€ ์‚ฌ๋žŒ์˜ ์™„์น˜์œจ์€ 18.5%์— ๋ถˆ๊ณผํ–ˆ์Šต๋‹ˆ๋‹ค. ๋˜ํ•œ ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ œ์ œ๋Š” ๊ธ‰์„ฑ ์ƒ์ฒ˜ ๋ฐ ํ™”์ƒ์˜ ์น˜์œ  ์‹œ๊ฐ„์„ ์ค„์ด๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค.

์—ฌ๋Ÿฌ ์—ฐ๊ตฌ์— ๋”ฐ๋ฅด๋ฉด ๋ฐ”๋ฅด๋Š” ์ œ์ œ์— ํ•จ์œ ๋œ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ํ”ผ๋ถ€ ์ˆ˜๋ถ„ ๋ฐ ํƒ„๋ ฅ์„ ์ฆ๊ฐ€์‹œํ‚ค๋ฉด์„œ ์ž”์ฃผ๋ฆ„์„ ๊ฐœ์„ ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์˜ ํšจ๊ณผ๋Š” ์ˆ˜๊ฐœ์›”์— ๊ฑธ์ณ ๋ˆ„์ ๋˜์–ด ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Šต๋‹ˆ๋‹ค. ํ•˜์ง€๋งŒ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๋ถ„์ž๊ฐ€ ์ปค์„œ ํ”ผ๋ถ€์— ์ž˜ ํก์ˆ˜๋˜์ง€ ์•Š๋Š”๋‹ค๋Š” ์ค‘์š”ํ•œ ๋‹จ์ ์ด ์žˆ์Šต๋‹ˆ๋‹ค. ๋ฐ”๋ฅด๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ œ์ œ๋Š” ์ด๋Ÿฌํ•œ ํก์ˆ˜ ๋ฌธ์ œ๋ฅผ ํ•ด๊ฒฐํ•˜๊ธฐ ์œ„ํ•œ ์ฒ˜๋ฆฌ ๊ณผ์ •์„ ๊ฑฐ์ณ์•ผ ํšจ๋Šฅ์„ ๋‚˜ํƒ€๋‚ผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ๋ฏธ์„ธ ๋ฐ ๋‚˜๋…ธ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ œ์ œ์˜ ํšจ๊ณผ๋Š” ์ด๋ฏธ ์ž…์ฆ๋œ ๋ฐ” ์žˆ์Šต๋‹ˆ๋‹ค. ํŽฉํƒ€์ด๋“œ ๊ฐ™์€ ์šด๋ฐ˜ ๋ฌผ์งˆ, ์Šคํ”ผํ˜(Spicule) ๊ฐ™์€ ๋ฏธ์„ธ๋ฐ”๋Š˜, ๋ฆฌํฌ์†œ(Liposome) ์ œ์ œ๋„ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์˜ ํก์ˆ˜์œจ์„ ๋†’์ด๋Š” ๋ฐ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

๊ฒฝ๊ตฌํ˜• ์ œ์ œ

ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๋Š” ์ œ์ œ์— ๋งŽ์ด ์‚ฌ์šฉ๋˜์ง€๋งŒ ๋ณด์ถฉ์ œ๋กœ ์„ญ์ทจํ•ด๋„ ํ”ผ๋ถ€ ๊ฑด๊ฐ•์„ ๋„์šธ ์ˆ˜ ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋ฐํ˜€์กŒ์Šต๋‹ˆ๋‹ค. ํ•œ ์—ฐ๊ตฌ์—์„œ๋Š” ๋น„ํƒ€๋ฏผC๋น„์˜คํ‹ด(Biotin)๊ตฌ๋ฆฌ์•„์—ฐ ๋“ฑ ํ”ผ๋ถ€์— ์ข‹์€ ์˜์–‘์†Œ์™€ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์„ ํ•จ๊ป˜ ์„ญ์ทจํ•˜๋ฉด ํ”ผ๋ถ€์— ์–ด๋–ค ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š”์ง€ ์กฐ์‚ฌํ–ˆ์Šต๋‹ˆ๋‹ค. ์—ฐ๊ตฌ ๊ฒฐ๊ณผ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ๋ณด์ถฉ์ œ๋Š” ํ”ผ๋ถ€ ํƒ„๋ ฅ๊ณผ ๋ณด์Šต ์ƒํƒœ๋ฅผ ํ–ฅ์ƒ์‹œํ‚ค๋Š” ๋™์‹œ์— ๊ฑฐ์นœ ํ”ผ๋ถ“๊ฒฐ๊ณผ ์ฃผ๋ฆ„ ๊นŠ์ด๋ฅผ ๊ฐœ์„ ํ•œ ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ์—ฐ๊ตฌ์ง„์€ 40์ผ๊ฐ„ ๋ณด์ถฉ์ œ๋ฅผ ์„ญ์ทจํ•˜๋Š” ๋™์•ˆ ์ด๋Ÿฌํ•œ ๊ธ์ •์ ์ธ ํšจ๊ณผ๊ฐ€ ๊ณ„์† ๋ˆ„์ ๋˜์–ด ๋‚˜ํƒ€๋‚œ ๊ฒƒ์œผ๋กœ ์ถ”์ •ํ–ˆ์Šต๋‹ˆ๋‹ค.

๊ธฐํƒ€ ํšจ๋Šฅ

ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ์ฃผ๋กœ ํ”ผ๋ถ€์— ์ข‹์€ ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ์ง€๋งŒ ์งˆํ™˜์„ ์น˜๋ฃŒํ•˜๋Š” ๋ฐ ์‚ฌ์šฉํ•˜๊ธฐ๋„ ํ•ฉ๋‹ˆ๋‹ค. ์˜ˆ๋ฅผ ๋“ค์–ด ๊ณจ๊ด€์ ˆ์—ผ ์ฆ์ƒ์„ ๊ด€๋ฆฌํ•˜๊ณ  ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•ด ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์„ ์ฃผ์ž…ํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์žˆ์Šต๋‹ˆ๋‹ค. ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์„ ๊ด€์ ˆ์— ์ง์ ‘ ์ฃผ์ž…ํ•˜๋ฉด ์œคํ™œ ํšจ๊ณผ๋ฅผ ํ†ตํ•ด ํ†ต์ฆ๊ณผ ์—ผ์ฆ์„ ์™„ํ™”ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์—ฐ๊ตฌ์— ๋”ฐ๋ฅด๋ฉด ๋ถ„์ž๊ฐ€ ํฐ ๊ณ ๋ถ„์ž ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ์ €๋ถ„์ž ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ๋ณด๋‹ค ๋” ํšจ๊ณผ์ ์ž…๋‹ˆ๋‹ค.

ํฅ๋ฏธ๋กญ๊ฒŒ๋„ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ๋ณด์ถฉ์ œ ์—ญ์‹œ ๋ฌด๋ฆŽ ํ†ต์ฆ์„ ๊ฐœ์„ ํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋ฐํ˜€์กŒ์Šต๋‹ˆ๋‹ค. ์—ฌ๋Ÿฌ ์ž„์ƒ์—ฐ๊ตฌ์— ๋”ฐ๋ฅด๋ฉด ๊ฒฝ๊ตฌ์šฉ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๋Œ€๋ถ€๋ถ„ ๋ถ€์ž‘์šฉ์ด ์—†์Šต๋‹ˆ๋‹ค.

ํ”ผ๋ถ€, ๊ด€์ ˆ๊ณผ ๋”๋ถˆ์–ด ๋ˆˆ์€ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์ด ๋†’์€ ๋†๋„๋กœ ๋ถ„ํฌํ•˜๋Š” ์‹ ์ฒด ๊ธฐ๊ด€์ž…๋‹ˆ๋‹ค. ์ด ๋•Œ๋ฌธ์— ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ์•ˆ๊ตฌ๊ฑด์กฐ์ฆ์„ ์น˜๋ฃŒํ•˜๋Š” ๋ฐ๋„ ์–ด๋Š ์ •๋„ ํšจ๊ณผ๊ฐ€ ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ์•ˆ๊ตฌ๊ฑด์กฐ์ฆ์„ ์™„ํ™”ํ•˜๋Š” ๋ˆˆ ์œคํ™œ์ œ๋กœ ์‚ฌ์šฉํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์ผ๋ฐ˜์ ์ด์ง€๋งŒ ๊ฒฝ๊ตฌ์šฉ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ๋ณด์ถฉ์ œ์™€ ๋ˆˆ ์œคํ™œ์ œ๋ฅผ ๋ณ‘์šฉํ–ˆ์„ ๋•Œ ์•ˆ๊ตฌ๊ฑด์กฐ์ฆ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ๋” ๋†’์•˜์Šต๋‹ˆ๋‹ค. ๊ทธ ์™ธ์— ๋ฐฑ๋‚ด์žฅ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•ด ์ฃผ์ž…ํ˜• ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์„ ์‚ฌ์šฉํ•˜๋Š” ๊ฒฝ์šฐ๋„ ์žˆ์Šต๋‹ˆ๋‹ค.

๊ฒฐ๋ก 

ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๊ฒฐํ•ฉ์กฐ์ง์„ ์ด๋ฃจ๋Š” ๊ตฌ์„ฑ์š”์†Œ๋กœ ํ”ผ๋ถ€, ๊ด€์ ˆ ๋“ฑ ๋‹ค์–‘ํ•œ ์‹ ์ฒด ์กฐ์ง์— ๋„์›€์ด ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ์œคํ™œ ์ž‘์šฉ๊ณผ ๊ตฌ์กฐ์  ํŠน์„ฑ์„ ํ†ตํ•ด ํšจ๋Šฅ์„ ๋‚˜ํƒ€๋‚ด๋Š” ๊ฒƒ์œผ๋กœ ์ถ”์ •๋ฉ๋‹ˆ๋‹ค. ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ํ”ผ๋ถ€ ์ฃผ์ž…์šฉ์œผ๋กœ ๋งŽ์ด ์‚ฌ์šฉํ•˜์ง€๋งŒ ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๊ฑฐ๋‚˜ ๊ฒฝ๊ตฌ๋กœ ์„ญ์ทจํ•˜๋Š” ํ˜•ํƒœ์˜ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ œ์ œ๋„ ํšจ๊ณผ๊ฐ€ ์žˆ์–ด ๋ณด์ž…๋‹ˆ๋‹ค. ๋˜ํ•œ ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ๋ณด์ถฉ์ œ๋Š” ๊ด€์ ˆ ํ†ต์ฆ ๋ฐ ๊ธฐ๋Šฅ์„ ๊ฐœ์„ ํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค. ์—ฐ๊ตฌ์— ๋”ฐ๋ฅด๋ฉด ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ์€ ๋Œ€์ฒด๋กœ ์•ˆ์ „ํ•˜๋ฉฐ ํ”ผ๋ถ€์— ๋ฐ”๋ฅด๊ฑฐ๋‚˜ ๊ฒฝ๊ตฌ๋กœ ์„ญ์ทจํ•˜๋Š” ํžˆ์•Œ๋ฃจ๋ก ์‚ฐ ์ œ์ œ๋Š” ํŠนํžˆ ๋ถ€์ž‘์šฉ์ด ์ ์Šต๋‹ˆ๋‹ค.

์ฐธ๊ณ ๋ฌธํ—Œ:

  1. Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis--meta-analysis. Osteoarthritis Cartilage. 2011;19(6):611-619. doi:10.1016/j.joca.2010.09.014
  2. Bowman S, Awad ME, Hamrick MW, Hunter M, Fulzele S. Recent advances in hyaluronic acid based therapy for osteoarthritis. Clin Transl Med. 2018;7(1):6. Published 2018 Feb 16. doi:10.1186/s40169-017-0180-3
  3. Bukhari SNA, Roswandi NL, Waqas M, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine: A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018;120(Pt B):1682-1695. doi:10.1016/j.ijbiomac.2018.09.188
  4. Chen M, Gupta V, Anselmo AC, Muraski JA, Mitragotri S. Topical delivery of hyaluronic acid into skin using SPACE-peptide carriers. J Control Release. 2014;173:67-74. doi:10.1016/j.jconrel.2013.10.007
  5. Gรถllner I, Voss W, von Hehn U, Kammerer S. Ingestion of an oral hyaluronan solution improves skin hydration, wrinkle reduction, elasticity, and skin roughness: results of a clinical study. J Evid Based Complementary Altern Med. 2017;22(1):96-106. doi:10.1177/2156587216641830
  6. Hummer CD, Angst F, Ngai W, et al. High molecular weight intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis. BMC Musculoskelet Disord. Published 2020 Oct 23. doi:10.1186/s12891-020-03729-w
  7. Hussain Z, Thu HE, Katas H, Bukhari SNA. Hyaluronic acid-based biomaterials: a versatile and smart approach to tissue regeneration and treating traumatic, surgical, and chronic wounds. Polymer Reviews. 2017;57(4):594-630.
  8. Imhof L, Leuthard D. Topical over-the-counter antiaging agents: an update and systematic review. Dermatology. 2021;237(2):217-229. doi:10.1159/000509296
  9. Jegasothy SM, Zabolotniaia V, Bielfeldt S. Efficacy of a new topical nano-hyaluronic acid in humans. J Clin Aesthet Dermatol. 2014;7(3):27-29.
  10. Kim Y, Moon CH, Kim BY, Jang SY. Oral hyaluronic acid supplementation for the treatment of dry eye disease: a pilot study. J Ophthalmol. 2019;2019:5491626. Published 2019 Sep 25. doi:10.1155/2019/5491626
  11. Lubart R, Yariv I, Fixler D, Lipovsky A. Topical hyaluronic acid facial cream with new micronized molecule technology effectively penetrates and improves facial skin quality: results from in-vitro, ex-vivo, and in-vivo (open-label) studies. J Clin Aesthet Dermatol. 2019;12(10):39-44.
  12. Mikosinski J, Di Landro A, ลuczak-Szymerska K, et al. efficacy and safety of a hyaluronic acid-containing gauze pad in the treatment of chronic venous or mixed-origin leg ulcers: a prospective, multicenter, randomized controlled trial. Wounds. 2021;33(6):147-157.
  13. Oe M, Tashiro T, Yoshida H, et al. Oral hyaluronan relieves knee pain: a review. Nutr J. 2016;15:11. Published 2016 Jan 27. doi:10.1186/s12937-016-0128-2
  14. Oranges CM, Brucato D, Schaefer DJ, Kalbermatten DF, Harder Y. Complications of nonpermanent facial fillers: a systematic review. Plast Reconstr Surg Glob Open. 2021;9(10):e3851. Published 2021 Oct 22. doi:10.1097/GOX.0000000000003851
  15. Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: a key molecule in skin aging. Dermatoendocrinol. 2012;4(3):253-258. doi:10.4161/derm.21923
  16. Ricci M, Micheloni GM, Berti M, et al. Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthritis. Musculoskelet Surg. 2017;101(1):45-49. doi:10.1007/s12306-016-0428-x
  17. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528-539. doi:10.1038/nrc1391
  18. Trinh LN, McGuigan KC, Gupta A. Delayed complications following dermal filler for tear trough augmentation: a systematic review [published online ahead of print, 2021 Oct 19]. Facial Plast Surg. 2021;10.1055/s-0041-1736390. doi:10.1055/s-0041-1736390
  19. Uitto J. Understanding premature skin aging. N Engl J Med. 1997;337(20):1463-1465. doi:10.1056/NEJM199711133372011
  20. Wang ST, Neo BH, Betts RJ. Glycosaminoglycans: sweet as sugar targets for topical skin anti-aging. Clin Cosmet Investig Dermatol. Published 2021 Sep 14. doi:10.2147/CCID.S328671
  21. Zhu J, Tang X, Jia Y, Ho CT, Huang Q. Applications and delivery mechanisms of hyaluronic acid used for topical/transdermal delivery - A review. Int J Pharm. 2020;578:119127. doi:10.1016/j.ijpharm.2020.119127